Glaxo first developed the vaccine in 1987 and has invested $300 million in it so far.
WHO said it couldn't comment on the incomplete results and would wait until the trial was finished before drawing any conclusions.
Copyright 2012 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.